Cannabis May Help Protect the Gut Lining During Cancer Treatment
Medicinal cannabis shows potential for managing mucositis and its cascading symptoms during cancer therapy by targeting inflammation, barrier function, and microbial balance in the gut.
Quick Facts
What This Study Found
The endocannabinoid system is densely distributed throughout the gut and modulates mucosal barrier integrity, inflammation, and microbial balance. Cannabis-based interventions could theoretically address mucositis and its downstream symptoms including diarrhea, nausea, infection, malnutrition, fatigue, depression, and insomnia through these interconnected pathways.
Key Numbers
Mucositis contributes to diarrhea, nausea, vomiting, infection, malnutrition, fatigue, depression, and insomnia in cancer patients. The endocannabinoid system modulates motility, inflammation, pain signaling, and barrier function throughout the gastrointestinal tract.
How They Did This
Narrative review outlining the biological rationale for medicinal cannabis in managing cancer therapy-induced mucositis. Synthesizes evidence on the endocannabinoid system in gut function, documented effects of cannabis on gastrointestinal symptoms, and the cascade of symptoms linked to mucosal barrier breakdown.
Why This Research Matters
Mucositis affects up to 100% of patients receiving certain cancer treatments and drives a cascade of debilitating symptoms. Current management treats each symptom in isolation. Cannabis's multi-target action on the gut endocannabinoid system could address the root cause rather than individual symptoms.
The Bigger Picture
Cancer supportive care has traditionally taken a "whack-a-mole" approach to side effects. Understanding mucositis as a driver of multiple downstream symptoms, and cannabis as a potential upstream intervention, could transform how we think about managing cancer treatment toxicity.
What This Study Doesn't Tell Us
This is a rationale paper, not a clinical study. No controlled trial data specifically test cannabis for mucositis prevention. The theoretical framework, while biologically plausible, requires clinical validation.
Questions This Raises
- ?Would prophylactic cannabis use before chemotherapy reduce mucositis incidence?
- ?Which cannabinoid formulations would best target gut mucosal protection?
- ?Could cannabis interfere with cancer treatment efficacy while protecting the gut?
Trust & Context
- Key Stat:
- Mucositis drives a cascade of symptoms: diarrhea, nausea, infection, fatigue, depression, and insomnia
- Evidence Grade:
- Preliminary: well-reasoned biological rationale supported by preclinical evidence, but lacks clinical trial data specific to cannabis and mucositis.
- Study Age:
- 2024 review.
- Original Title:
- Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges.
- Published In:
- British journal of cancer, 130(1), 19-30 (2024)
- Authors:
- Wardill, Hannah R, Wooley, Luke T, Bellas, Olivia M, Cao, Katrina, Cross, Courtney B, van Dyk, Madele, Kichenadasse, Ganessan, Bowen, Joanne M, Zannettino, Andrew C W, Shakib, Sepehr, Crawford, Gregory B, Boublik, Jaroslav, Davis, Mellar M, Smid, Scott D, Price, Timothy J
- Database ID:
- RTHC-05801
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is mucositis?
Mucositis is the breakdown of the mucosal lining of the digestive tract caused by chemotherapy or radiation. It causes pain, ulcers, and barrier dysfunction that allows bacteria to enter the bloodstream and triggers a chain of other symptoms.
How could cannabis help with mucositis?
The endocannabinoid system is densely present in the gut and regulates inflammation, barrier integrity, motility, and pain signaling. Cannabis compounds interact with this system and could theoretically protect or repair the mucosal barrier during cancer treatment.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- cannabis-and-ibs-gut-health-inflammation
- cannabis-and-crohns-disease-gastroenterology
Cite This Study
https://rethinkthc.com/research/RTHC-05801APA
Wardill, Hannah R; Wooley, Luke T; Bellas, Olivia M; Cao, Katrina; Cross, Courtney B; van Dyk, Madele; Kichenadasse, Ganessan; Bowen, Joanne M; Zannettino, Andrew C W; Shakib, Sepehr; Crawford, Gregory B; Boublik, Jaroslav; Davis, Mellar M; Smid, Scott D; Price, Timothy J. (2024). Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges.. British journal of cancer, 130(1), 19-30. https://doi.org/10.1038/s41416-023-02466-w
MLA
Wardill, Hannah R, et al. "Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges.." British journal of cancer, 2024. https://doi.org/10.1038/s41416-023-02466-w
RethinkTHC
RethinkTHC Research Database. "Supporting gut health with medicinal cannabis in people with..." RTHC-05801. Retrieved from https://rethinkthc.com/research/wardill-2024-supporting-gut-health-with
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.